Study Title
A Multicentre, Prospective, Open-label Study With [68Ga]Ga-ABY-025 PET-imaging to Characterize HER2-expression and Explore the Therapy-predictive Value for HER2-antibody Drug Conjugates in Patients With Metastatic Breast Cancer
Study Details
Description:
This is a prospective, multi-center, open-label, exploratory diagnostic phase II imaging trial for patients with metastatic breast cancer with at least one line of systemic therapy.
Sponsor:
Henske Altena
Contacts:
Renske Altena, MD, PHDrenske.altena@ki.se
Thuy Tran, Associate Prof, PharmD, PhD (Associate Professor)thuy.tran@regionstockholm.se
+46812377777
Government Study Link:
NCT06830382 - Click here to see study onClinicalTrials.gov
Drug Details
[68Ga]Ga-ABY-025
Isotope(s):
- GALLIUM-68
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- HER2
